Company / Current Liabilities
Esperion Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$300.8M
FY2025
5-year range
$73.4M / $300.8M
FY2021-FY2025
Trend
+22.2%
vs FY2024
Sector context
#45 of 213
Health Care
What the data says
Esperion Therapeutics, Inc.'s current liabilities of $301M is higher than 79% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 4 consecutive years, from $73M in FY2021 to $301M in FY2025.
Based on SEC 10-K filings.
$301M in FY2025 with a 5-year CAGR of +26.2%. Top quartile in the Health Care sector.
Increased from $156M to $301M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +48.3%
- 5-Year CAGR
- +26.2%
- 10-Year CAGR
- -
Sector benchmark
-81.1% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s current liabilities has grown for 4 consecutive years.
- 5-year CAGR of +26.2%, indicating consistent growth.
- In FY2025, current liabilities increased 22.2% year-over-year.
- Ranks #45 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $300.8M | +22.2% |
| FY2024 | $246.2M | +57.6% |
| FY2023 | $156.2M | +69.2% |
| FY2022 | $92.3M | +25.8% |
| FY2021 | $73.4M | -22.0% |
| FY2020 | $94.1M | +42.4% |
| FY2019 | $66.1M | +2.7% |
| FY2018 | $64.3M | +94.1% |
| FY2017 | $33.1M | +112.6% |
| FY2016 | $15.6M | +177.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026